Staged Cardiac and Aortic Aneurysm Surgery Using Ventricular Assist Device

1997 ◽  
Vol 5 (2) ◽  
pp. 107-108
Author(s):  
Ryousuke Matsuwaka ◽  
Yasuhisa Shimazaki ◽  
Yuji Miyamoto ◽  
Takafumi Masai ◽  
Hideo Shintani ◽  
...  
Keyword(s):  
Aortic Aneurysm ◽  
Ventricular Assist Device ◽  
Artery Bypass ◽  
Abdominal Aortic Aneurysm Repair ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Risk Patients ◽  
Aortic Aneurysm Surgery ◽  
Two Stages

A two-stage procedure involving coronary artery bypass grafting and aortic valve replacement followed by abdominal aortic aneurysm repair two days later was performed on a 51-year-old man with severely depressed left ventricular function. The patient was supported with a left ventricular assist device as a short-term bridge between the two stages of surgery. This strategy may be a useful alternative to a one-stage operation in high-risk patients.

scholarly journals Combined Left Ventricular Assist Device and Coronary Artery Bypass Grafting Surgery

ASAIO Journal ◽  
2020 ◽  
Vol 66 (1) ◽  
pp. 32-37 ◽  
Author(s):  
Priya Mehta ◽  
Teruhiko Imamura ◽  
Colleen Juricek ◽  
Nitasha Sarswat ◽  
Gene Kim ◽  
...  
Keyword(s):  
Coronary Artery ◽  
Coronary Artery Bypass Grafting ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Artery Bypass ◽  
Left Ventricular ◽  
Bypass Grafting ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist

scholarly journals Applying a clampless haemostatic device for left ventricular assist device outflow graft anastomosis

2019 ◽  
Vol 56 (5) ◽  
pp. 1009-1010
Author(s):  
Arash Mehdiani ◽  
Alexander Albert ◽  
Artur Lichtenberg ◽  
Diyar Saeed
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Artery Bypass ◽  
Left Ventricular ◽  
Related Complication ◽  
Assist Device ◽  
Ventricular Assist ◽  
Vein Grafts ◽  
Left Ventricular Assist ◽  
Outflow Graft

Abstract Performing a left ventricular assist device outflow graft anastomosis in redo cases with a short ascending aorta and open vein grafts requires side clamping of the aorta and may necessitate temporary clamping of the vein grafts to optimize the surgical field. We aim to describe the technique and report our experience with applying the HeartString® device for the anastomosis of the left ventricular assist device outflow graft in 2 male patients with ischaemic cardiomyopathy following coronary artery bypass surgery. The feasibility of using the HeartString device has been shown and no procedure-related complication was documented.

scholarly journals Planned Concomitant Left and Right Ventricular Assist Device Insertion to Avoid Long-term Biventricular Mechanical Support: Bridge to Right Ventricular Recovery

2018 ◽  
Vol 21 (5) ◽  
pp. E412-E414 ◽  
Author(s):  
Michael Salna ◽  
Yasuhiro Shudo ◽  
Jeffrey J Teuteberg ◽  
Dipanjan Banerjee ◽  
Richard V. Ha ◽  
...  
Keyword(s):  
Right Ventricular ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Mechanical Support ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist ◽  
Risk Patients ◽  
Right Ventricular Assist Device

Introduction: The planned use of a temporary right ventricular assist device (RVAD) at the time of left ventricular assist device (LVAD) implantation may prevent the need for a permanent biventricular assist device (BiVAD). Herein we describe our RVAD weaning protocol that was effectively employed in 4 patients to prevent the need for permanent BiVAD. Methods: Four patients in refractory cardiogenic shock underwent planned RVAD insertion during LVAD implantation due to severely depressed right ventricular function with dilation preoperatively. A standardized RVAD weaning protocol was employed in these 4 patients in preparation for decannulation. Results: Temporary RVADs were successfully placed in all 4 patients at the time of LVAD implantation. All patients survived to RVAD decannulation and discharge and were alive at the time of most recent follow-up (range, 528-742 days post–RVAD decannulation). Conclusion: Planned implantation of a temporary RVAD in high risk patients may avoid the need for biventricular mechanical support in the future.

Early Outcomes of the First 200 US Patients Treated with Impella 5.5: A Novel Temporary Left Ventricular Assist Device

2021 ◽  
pp. 155698452110133
Author(s):  
Danny Ramzy ◽  
Mark Anderson ◽  
George Batsides ◽  
Masahiro Ono ◽  
Scott Silvestry ◽  
...  
Keyword(s):  
Overall Survival ◽  
Cardiogenic Shock ◽  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Artery Bypass ◽  
Bypass Graft ◽  
Left Ventricular ◽  
Assist Device ◽  
Ventricular Assist ◽  
Left Ventricular Assist

Objective To report the initial clinical experience with the Impella 5.5® with SmartAssist®, a temporary left ventricular assist device that provides up to 6.2 L/min forward flow, with recent FDA approval for up to 14 days. Methods From October 2019 to March 2020, 200 patients at 42 US centers received the Impella 5.5 and entered into the IQ registry, a manufacturer-maintained quality database that captures limited baseline/procedural characteristics and outcomes through device explant. Post hoc subgroup analyses were conducted to assess the role of baseline and procedural characteristics on survival, defined as successful device weaning or bridge to durable therapy. Results Median patient age was 62 years (range, 13 to 83 years); 83.4% were male. The device was most commonly used for cardiomyopathy (45.0%), acute myocardial infarction complicated by cardiogenic shock (AMICS; 29.0%), and post cardiotomy cardiogenic shock (PCCS; 16.5%). Median duration of support was 10.0 days (range, 0.001 to 64.4 days). Through device explant, overall survival was 74.0%, with survival of 80.0%, 67.2%, 57.6%, and 94.7% in cardiomyopathy, AMICS, PCCS, and others (comprising high-risk revascularization, coronary artery bypass graft, electrophysiology/ablation, and myocarditis), respectively. Patients requiring extracorporeal membrane oxygenation and Impella support (35 patients, 17.5%) had significantly lower survival (51.4% vs 78.8%, P = 0.002). Conclusions In the first 200 US patients treated with the Impella 5.5, we observed overall survival to explant of 74%. Survival outcomes were improved compared to historic rates observed with cardiogenic shock, particularly PCCS. Prospective studies assessing comparative performance of this device to conventional strategies are warranted in future.

Ultrastructural observations of the aorta of calves implanted with a mechanical left ventricular assist device

1990 ◽  
Vol 48 (3) ◽  
pp. 834-835
Author(s):  
J P Cassella ◽  
V Salih ◽  
T R Graham
Keyword(s):  
Left Ventricular Assist Device ◽  
Ventricular Assist Device ◽  
Left Ventricular ◽  
Aortic Tissue ◽  
Assist Device ◽  
Ventricular Assist ◽  
Transmission Electron ◽  
Left Ventricular Assist ◽  
Preliminary Study

Left ventricular assist systems are being developed for eventual long term or permanent implantation as an alternative to heart transplantation in patients unsuitable for or denied the transplant option. Evaluation of the effects of these devices upon normal physiology is required. A preliminary study was conducted to evaluate the morphology of aortic tissue from calves implanted with a pneumatic Left Ventricular Assist device-LVAD. Two 3 month old heifer calves (calf 1 and calf 2) were electively explanted after 128 days and 47 days respectively. Descending thoracic aortic tissue from both animals was removed immediately post mortem and placed into karnovsky’s fixative. The tissue was subsequently processed for transmission electron microscopy (TEM). Some aortic tissue was fixed in neutral buffered formalin and processed for routine light microscopy.

Sign in / Sign up

Export Citation Format

Share Document